Skip to main
CING

Cingulate (CING) Stock Forecast & Price Target

Cingulate (CING) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cingulate Inc. is strategically positioned in the growing ADHD medication market, which has experienced approximately 8% annual growth, reaching around $18 billion in 2020, indicating a strong demand for its products. The company is advancing its proprietary medications, CTx-1301 and CTx-1302, with expected approval and commercialization timelines around mid to late-2026, presenting potential catalysts for significant stock value appreciation. Additionally, the current valuation of Cingulate's stock is considered attractive, reflecting an opportunity where the risk versus reward dynamic remains favorable amid the overall market potential for ADHD treatments.

Bears say

Cingulate Inc reported a net loss of $7.3 million, representing an earnings per share (EPS) of $(1.35), which was significantly worse than both internal estimates of $(0.79) and consensus expectations of $(0.81). Additionally, the company's prior net loss of $6.5 million, with an EPS of $(0.93), also fell short of estimated and consensus figures. The company faces several notable risks, including liquidity challenges, potential failures in clinical trial outcomes for its product candidates, regulatory approval obstacles, and competitive pressures, all of which underscore a negative outlook for its financial stability and stock performance.

Cingulate (CING) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cingulate (CING) Forecast

Analysts have given Cingulate (CING) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Cingulate (CING) has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cingulate (CING)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.